Phuyal Prabin, Bokhari Sabahat
Department of Medicine, Saint Peter's University Hospital/Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA.
Rev Cardiovasc Med. 2024 Feb 5;25(2):61. doi: 10.31083/j.rcm2502061. eCollection 2024 Feb.
Cardiac amyloidosis is a great masquerader that often results in misdiagnosis of this condition. Early clinical recognition is crucial for timely therapeutic interventions to improve survival in patients with cardiac amyloidosis. Currently, Food and Drug Administration (FDA)-approved medications work best if started early in the disease. Thus, to increase identification, disease awareness, expertise in diagnostic techniques, and a multidisciplinary team approach is essential. The majority of the patients (~90%) in the United States are treated in community hospitals, thus, it would be helpful for these hospitals to have their own designated, comprehensive cardiac amyloidosis center to provide care to the patients who are widespread in the community. Most of these patients are elderly, and it is difficult for these patients to travel long distances to academic amyloid centers. Our manuscript aims to provide a path to the development of cardiac amyloid centers at community hospitals.
心脏淀粉样变性是一种极具伪装性的疾病，常常导致对该病症的误诊。早期临床识别对于及时进行治疗干预以提高心脏淀粉样变性患者的生存率至关重要。目前，美国食品药品监督管理局（FDA）批准的药物如果在疾病早期开始使用，效果最佳。因此，为了提高识别率，疾病认知、诊断技术方面的专业知识以及多学科团队方法至关重要。在美国，大多数患者（约90%）在社区医院接受治疗，因此，这些医院拥有自己指定的综合性心脏淀粉样变性中心，以便为社区中广泛分布的患者提供护理，将会有所帮助。这些患者大多数是老年人，让他们长途跋涉前往学术性淀粉样变性中心很困难。我们的手稿旨在为社区医院心脏淀粉样变性中心的发展提供一条途径。
